Monthly prophylactic injections of fitusiran are effective in reducing bleeds in patients with haemophillia A or B, according to randomised controlled trials publishing simultaneously in The Lancet ...

Both Phase 3 studies achieved their primary and secondary endpoints; fitusiran prophylaxis demonstrated significant and clinically meaningful improvements in bleed protection across all hemophilia ...

In the first analysis to estimate the gap between global supply and demand of blood, scientists have found that many countries are critically short of blood, according to a modelling study published ...

Combination in r/r follicular lymphoma shows best ORR of 97% and CR rate of 77% with 12-month PFS of 95% Additional IIT data also presented at ASH on ZYNLONTA monotherapy in marginal zone lymphoma ...

1 Press Release HUTCHMED Highlights Publication of Phase III ESLIM-01 Results in The Lancet Haematology — Publication shows treatment demonstrated durable response rate of 48.4% vs. 0% with placebo — ...

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE:ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat ...

Sanofi (NASDAQ:SNY) said two phase 3 studies published in The Lancet and The Lancet Haematology, highlighted the potential of hemophilia prevention therapy fitusiran. Sanofi had gained the rights to ...

SHANGHAI, Oct. 7, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the results of CT071 ...

The Lancet Haematology is an exclusively online journal dedicated to publishing original research that advocates change in, or illuminates, haematological clinical practice, including, but not limited ...

SOUTH SAN FRANCISCO, Calif., April 08, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced The Lancet Haematology has published the complete analysis of ...